Abstract | BACKGROUND: METHODS: After obtaining serum folate, B12, and hematological indices, 213 depressed adults were treated with fluoxetine 20 mg/day. Amelioration of depressive symptoms was measured. RESULTS: Neither macrocytosis nor anemia predicted low serum folate/B12, or antidepressant refractoriness. Among 39 patients with hypofolatemia, none had macrocytosis; 28% had low HCT; 41% had low RBC. Among 25 patients with low B12, none had macrocytosis; 24% had low HCT; 28% had low RBC. Among non-responders, 3% had macrocytosis; 24% had low HCT; 25% had low RBC. CONCLUSION:
Anemia and macrocytosis should not be used to predict folate or B12 deficiencies, or refractoriness to antidepressants. Measurement of folate and B12 should be considered when evaluating treatment refractoriness.
|
Authors | D Mischoulon, J K Burger, M K Spillmann, J J Worthington, M Fava, J E Alpert |
Journal | Journal of psychosomatic research
(J Psychosom Res)
Vol. 49
Issue 3
Pg. 183-7
(Sep 2000)
ISSN: 0022-3999 [Print] England |
PMID | 11110989
(Publication Type: Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antidepressive Agents, Second-Generation
- Fluoxetine
|
Topics |
- Adult
- Anemia, Macrocytic
(blood, psychology)
- Antidepressive Agents, Second-Generation
(therapeutic use)
- Depressive Disorder, Major
(blood, drug therapy)
- Drug Tolerance
- Erythrocyte Count
- Female
- Fluoxetine
(therapeutic use)
- Folic Acid Deficiency
(blood, psychology)
- Humans
- Male
- Middle Aged
- Predictive Value of Tests
- Psychiatric Status Rating Scales
- Regression Analysis
- Treatment Outcome
- Vitamin B 12 Deficiency
(blood, psychology)
|